Acinetobacter baumannii is a bacterial pathogen of increasing medical importance. Little is known about its mechanisms of pathogenesis, and safe reliable agents with predictable activity against A. baumannii are presently nonexistent. The availability of relevant animal infection models will facilitate the study of Acinetobacter baumannii biology. In this report we tested the hypothesis that the rat pneumonia and soft-tissue infection models that our laboratory had previously used for studies of extraintestinal pathogenic Escherichia coli were clinically relevant for A. baumannii. Advantages of these models over previously described models were that the animals were not rendered neutropenic and they did not receive porcine mucin with bacterial challenge. Using the A. baumannii model pathogen 307-0294 as the challenge pathogen, the pneumonia model demonstrated all of the features of infection that are critical for a clinically relevant model: namely, bacterial growth/clearance, an ensuing host inflammatory response, acute lung injury, and, following progressive bacterial proliferation, death due to respiratory failure. We were also able to demonstrate growth of 307-0294 in the soft-tissue infection model. Next we tested the hypothesis that the soft-tissue infection model could be used to discriminate between the inherent differences in virulence of various A. baumannii clinical isolates. The ability of A. baumannii to grow and/or be cleared in this model was dependent on the challenge strain. We also hypothesized that complement is an important host factor in protecting against A. baumannii infection in vivo. In support of this hypothesis was the observation that the serum sensitivity of various A. baumannii clinical isolates in vitro roughly paralleled their growth/clearance in the soft-tissue infection model in vivo. Lastly we hypothesized that the soft-tissue infection model would serve as an efficient screening mechanism for identifying gene essentiality for drug discovery. Random mutants of 307-0294 were initially screened for lack of growth in human ascites in vitro. Selected mutants were subsequently used for challenge in the soft-tissue infection model to determine if the disrupted gene was essential for growth in vivo. Using this approach, we have been able to successfully identify a number of genes essential for the growth of 307-0294 in vivo. In summary, these models are clinically relevant and can be used to study the innate virulence of various Acinetobacter clinical isolates and to assess potential virulence factors, vaccine candidates, and drug targets in vivo and can be used for pharmacokinetic and chemotherapeutic investigations.
antibiotic-resistant strains is making treatment challenging (17, 29, 32, 45, 47, 50). Particularly problematic are panresistant strains. In a 1999 New York City outbreak, 12% of Acinetobacter baumannii isolates were resistant to all standard antimicrobials (23). These rates are higher outside the United States. Safe reliable agents with predictable activity against A. baumannii are presently nonexistent.

The need for an increased understanding of Acinetobacter pathogenesis, identification of virulence factors, and the identification and testing of vaccine candidates and new antimicrobial targets is more pressing than ever (28, 46). In order to accomplish these goals it is critical to identify/develop relevant animal models of infection. To date, Acinetobacter has been used in a variety of animal models, including murine (21, 22, 25, 26, 31, 36) and guinea pig (4) pneumonia models, a rat thigh infection model (27), and a rabbit endocarditis model (35). However, the clinical relevance and suitability of these models vary depending on the hypothesis being tested. In this report we tested the hypothesis that the rat pneumonia and soft-tissue infection models that our laboratory had previously used for studies of extraintestinal pathogenic Escherichia coli were clinically relevant for studying A. baumannii infection. Next we tested the hypothesis that the soft-tissue infection model could be used to discriminate between the inherent differences in virulence of various A. baumannii clinical isolates. We also hypothesized that complement is an important host factor in protecting against A. baumannii infection in vivo. Lastly we hypothesized that the soft-tissue infection model would serve as an efficient screening mechanism for establishing gene essentiality for drug discovery. The results suggest that these models are well suited and clinically relevant for testing and answering a variety of questions related to infections due to A. baumannii.

MATERIALS AND METHODS

Bacterial strains and media. A. baumannii strain 307-0294 (blood isolate, sequence type 15 [ST15], clonal group I based on the work of Ecker et al. [12]) was isolated from a patient hospitalized at Erie County Medical Center, Buffalo, NY. A. baumannii strains 855 (OIFC031) (blood isolate, ST11, clonal group II), 855 (OIFC075V) (asialyl isolate, ST14, clonal group III), 900 (OIFC111) (peripheral isolate, ST19, clonal group undetermined), and 979 (OIFC327) (environmental isolate, ST24, clonal group undetermined) were isolated from infected military personnel serving in Iraq and Afghanistan (kindly provided by David Craft and Paul Scott of the Walter Reed Army Medical Center). All strains were characterized by multilocus sequence typing (35). In a 1999 New York City outbreak, 12% of A. baumannii isolates were resistant to all standard antimicrobials (23). These rates are higher outside the United States. Safe reliable agents with predictable activity against A. baumannii are presently nonexistent.

(i) Assessment of bacterial growth/clearance. Intact, excised post-BAL lungs were weighed and suspended in normal saline to a total weight of 10 g (assumed to equate to 10 ml). The addition of saline served as a vehicle for homogenization and to generate a constant volume for each so that titers could be easily calculated. Lungs were then homogenized on ice (three bursts of 3-s duration each) using a Polytron PT-2000 homogenizer (Brinkman Instruments, Westbury, NY). Total Acinetobacter titers were determined by enumerating combined bacteria in BALF plus post-BAL lung tissue as described previously (41).

(ii) Assessment of the pulmonary host response. (a) Measurement of rat TNF-α, IL-1β, and CINC-1 levels in BALF. Sandwich enzyme-linked immunosorbent assays utilizing commercial antibodies and standards (R&D Systems Inc., Minneapolis, MN) were used for measuring levels of rat tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), and cytokine-induced neutrophil chemoattractant 1 (CINC-1) as described previously (40).

(b) Measurement of BALF cell counts. A 50-μl aliquot was diluted 1:200 in isotonic II solution (Beckman Coulter), and the leukocyte concentration was determined using a Multisizer 3 Coulter Counter (Beckman Coulter). A cytoslide was prepared by diluting cells to a final concentration of 5 × 10^6 leukocytes/ml, stained with Diff-Quik reagents (Baxter, Miami, FL), and examined by light microscopy (Nikon Microscope ECLIPSE 80i; Nikon Instruments Inc., Melville, NY).

(iii) Assessment of lung injury. Arterial blood oxygenation was measured (ABL5; Radiometer America, Westlake, OH) and reported as the arterial partial pressure of oxygen divided by the fraction of inspired oxygen (PaO2/FiO2 ratio). Albumin concentrations in cell-free BAL were measured by enzyme-linked immunosorbent assay using a polyclonal rabbit anti-mouse albumin antibody (a gift from Daniel Remick, University of Michigan, Ann Arbor, MI) and horseradish peroxidase-labeled goat anti-rabbit immunoglobulin (Pharmingen, San Diego, CA) (9). Rat albumin (Sigma, St. Louis, MO) was used as a standard.

Rat soft-tissue infection model. Long-Evans rats (200 to 250 g) were anesthetized as described for the pneumonia model. A subcutaneous space was created over the back of each by injecting 0.2 ml of air subcutaneously. A 0.2-ml aliquot of a mixture of sterile vegetable oil (975 μl) and croton oil (25 μl) in the space created. After 7 days this resulted in an encapsulated “pouch” that was filled with an exudative fluid (pouch fluid), mimicking a subcutaneous abscess. This model has been well characterized (7, 8). It is a dynamic model, as evidenced by the fact that neutrophils will migrate into the pouch in response to appropriate stimuli. Bacteria can be introduced into the pouch, and pouch fluid can be easily removed over time, enabling the study of both microbial and host responses. On day 8, approximately 5 × 10^6 CFU of the A. baumannii strain being assessed was injected into the pouches of anesthetized animals, resulting in estimated starting pouch concentrations of 1 × 10^9 to 2 × 10^8 CFU/ml. Within 1 minute after the bacteria were injected into the pouch, 0.5 ml of pouch fluid was removed to measure the actual starting bacterial titer. Fluid aliquots (0.5 ml) were subsequently obtained from anesthetized animals 3, 6, 24, and 48 h after the initial bacterial challenge, and bacterial titers were determined by enumerating bacterial CFU in pouch fluid by serial 10-fold dilutions in 1× PBS.

Serum bactericidal assay. Complement-mediated bactericidal assays were performed by measuring the change in bacterial titer over time in the presence of 90% active or inactive (heated at 56°C for 30 min) human serum. An input bacterial titer of approximately 1 × 10^9 CFU was utilized, and titers were measured at 0, 1, 2, and 3 h as described previously (38, 43).

Transposon mutagenesis and complement for lack of growth on ascites plates. Electroeoptomized cells were grown by growing AB307-0294 in Mueller-Hinton (MH) broth to an A600 of around 0.4. Fifteen milliliter cultures were washed once with 1 ml of ice-cold sterile milli-Q-filtered H2O (Millipore, Billerica, MA), followed by two washes with 10% ice-cold, sterile glycerol. After the last wash, the cells were
FIG. 1. Growth/clearance of different titers of A. baumannii strain 307-0294 in the rat pneumonia model. Rats were challenged with 7.0 × 10^6, 5.8 × 10^5, 3.5 × 10^5, 4.3 × 10^4, and 7.7 × 10^3 CFU of 307-0294 (blood isolate, ST15, clonal group 1) by intratracheal instillation, and total lung bacterial titers were determined at 0, 3, 6, 24, 48, 72, and 168 h. Data are means ± standard errors of the means for n = 3 for each challenge titer and time point.

FIG. 2. Survival of rats in the pneumonia model post-challenge with different titers of A. baumannii strain 307-0294. Rats were challenged with 7.0 × 10^6 (n = 18), 5.8 × 10^5 (n = 19), 3.5 × 10^5 (n = 19), 4.3 × 10^4 (n = 18), and 7.7 × 10^3 (n = 18) CFU of 307-0294 by intratracheal instillation, and survival was recorded. There was a trend for increased survival in rats challenged with 7.0 × 10^6 and 5.8 × 10^5 CFU compared to rats challenged with 7.7 × 10^3 CFU (&, P = 0.03).

Results

The rat pneumonia model is clinically relevant for assessing Acinetobacter infection. Acinetobacter is capable of causing both community-acquired and nosocomial pneumonia. Therefore, we tested the hypothesis that the immunocompetent rat pneumonia model that our laboratory had previously used for studies of extraintestinal pathogenic E. coli was clinically relevant for A. baumannii (39–42). The pertinent features of gram-negative bacterial pneumonia were evaluated: namely, bacterial growth (or clearance), the ensuing host inflammatory response, acute lung injury, and death due to respiratory failure following progressive bacterial proliferation.

Bacterial growth/clearance. Rats underwent intratracheal challenge with various titers (7.0 × 10^6 to 7.7 × 10^3 CFU) of A. baumannii strain 307-0294 (blood isolate, ST15, clonal group 1) to determine whether growth or clearance occurred in this in vivo pneumonia model over 7 days (Fig. 1). Overall, growth/clearance roughly correlated with the magnitude of the challenge inoculum. For the highest challenge titer (7.7 × 10^3 CFU) net growth occurred over the first 48 h, and for the next two highest challenge titers (3.5 × 10^5 and 4.3 × 10^4 CFU) net growth occurred over the first 24 h. However, by 72 h net clearance occurred for all challenge titers. By day 7, although clearance occurred for all challenge titers, it was not complete. Taken together, these data support the contention that A. baumannii is able to survive and grow in the rat pneumonia model and that this is dependent on the challenge inoculum.

Survival. Rats underwent intratracheal challenge with various titers (7.0 × 10^6 to 7.7 × 10^3 CFU) of 307-0294 to determine if mortality occurred in this in vivo pneumonia model over 7 days (Fig. 2). No deaths occurred after challenge with 7.0 × 10^6 (n = 18), 5.8 × 10^5 (n = 19), and 4.3 × 10^4 (n = 18) CFU. Two and four deaths occurred 24 to 48 h after challenge with 3.5 × 10^5 (n = 19) and 7.7 × 10^3 (n = 18) CFU, respectively. There was a trend for increased survival in rats challenged with 7.0 × 10^6 and 5.8 × 10^5 CFU compared to rats challenged with 7.7 × 10^3 CFU (P = 0.03). These data support the contention that A. baumannii is able to cause lethal pulmonary infection in the rat pneumonia model and that this is dependent on the challenge inoculum.

Further, growth/clearance (see “Bacterial growth/clearance” above), oxygenation, and BALF albumin data (see “Acute lung injury” below) suggest that death, at least in part, is due to progressive bacterial proliferation and associated respiratory failure.
Acute lung injury. To determine the effect of *A. baumannii* on acute lung injury, arterial oxygenation (PaO_2/FiO_2 ratio) and BALF albumin were measured at 3, 6, 24, 48, 72, and 168 h following challenge of rats with various titers of 307-0294. After challenge with 307-0294, the decreases in oxygenation levels, which reflect acute lung injury, were similar and most pronounced with the three highest challenge inocula (3.5 × 10^6 to 7.7 × 10^7 CFU). A lesser effect on oxygenation was observed with the two lowest challenge inocula (7.0 × 10^6 and 5.8 × 10^7 CFU) (Fig. 3). The greatest decrease in oxygenation occurred at 24 h for the three highest 307-0294 challenge inocula (3.5 × 10^6 to 7.7 × 10^7 CFU), at 48 h for the next highest challenge inoculum (5.8 × 10^7 CFU), and at 72 h for the lowest challenge inoculum (7.0 × 10^6 CFU). Levels recovered thereafter but not back to baseline. There was a trend for increased oxygenation at 24 h in rats challenged with 7.0 × 10^6 CFU compared to rats challenged with 3.5 × 10^6 and 7.7 × 10^6 CFU (Fig. 3). These data demonstrated that the increase in BALF albumin occurred at 24 h for the three highest 307-0294 challenge inocula (3.5 × 10^6 to 7.7 × 10^7 CFU) and at 6 h for the two lowest challenge inocula (5.8 × 10^7 and 7.0 × 10^6 CFU); levels decreased thereafter. There was a significant decrease or trend toward a significant decrease in the concentration of BALF albumin at various times in rats challenged with 7.0 × 10^6 and 5.8 × 10^7 CFU compared to rats challenged with 3.5 × 10^6, 4.3 × 10^6, and 7.7 × 10^6 CFU (Fig. 4). These data demonstrated that the increase in BALF albumin was greatest when *A. baumannii* was able to grow (e.g., 307-0294 challenge inocula of 3.5 × 10^7 to 7.7 × 10^9 CFU) compared to when *A. baumannii* was cleared (e.g., 307-0294 challenge inocula of 7.0 × 10^6 and 5.8 × 10^7 CFU).

Host inflammatory response. To determine the effect of *A. baumannii* on pulmonary levels of TNF-α, IL-1β, and CINC-1 in vivo, these mediators were assessed in cell-free BALF supernatants at 3, 6, 24, 48, 72, and 168 h following challenge of rats with various titers of 307-0294. After challenge with 307-0294, levels of TNF-α, IL-1β, and CINC-1 were barely measurable after a challenge inoculum of 7.0 × 10^6 CFU, increased after a challenge inoculum of 5.7 × 10^7 CFU, and were of similar orders of magnitude after challenge inocula of 3.5 × 10^6, 4.3 × 10^6, and 7.7 × 10^6 CFU (Fig. 5A to C). After challenge with 307-0294, TNF-α and CINC-1 levels peaked at 6 h and essentially were at the limit of detection by 72 h (Fig. 5A and C), whereas IL-1β levels peaked at 24 h and were at the
limit of detection by 72 h (Fig. 5B). There was a significant decrease or trend toward a significant decrease in TNF-α, IL-1β, and CINC-1 levels at various times in rats challenged with 7.0 × 10^9 and 5.8 × 10^8 CFU compared to rats challenged with 3.5 × 10^9, 4.3 × 10^8, and 7.7 × 10^8 CFU (Fig. 5). These data demonstrated that after challenge with 307-0294 levels of TNF-α, IL-1β, and CINC-1 increased with increasing challenge inocula from 7.0 × 10^6 to 3.5 × 10^9 CFU and reached plateau levels thereafter. Further, levels of these early proinflammatory cytokines decreased after 6 h for TNF-α and CINC-1 and after 24 h for IL-1β. These data support the contention that the magnitude of the challenge inoculum is the dominant factor affecting levels of TNF-α, IL-1β, and CINC-1.

Pulmonary neutrophils present in BALF were also assessed after challenge with various titers of 307-0294 (except for the 7.7 × 10^8 CFU challenge inoculum). Neutrophil counts peaked at 6 h and decreased thereafter (Fig. 6). The total numbers of neutrophils were similar after challenge with all titers of 307-0294, except after challenge with the lowest titer (7.0 × 10^6 CFU) at 24, 48, 72, and 168 h, where there was a significant decrease or a trend toward a significant decrease in the number of neutrophils compared to that for rats challenged with 5.7 × 10^7, 3.5 × 10^8, and 4.3 × 10^8 CFU (Fig. 6). The timing of maximal neutrophil counts corresponded to the timing of maximal TNF-α and CINC-1 levels, but unlike cytokines, neutrophil counts decreased more slowly and persisted for 168 h. Further, the maximal neutrophil response was seen even with the lowest 307-0294 challenge titers.

Taken together, these data demonstrate that bacterial growth, acute lung injury, and an appropriate host inflammatory response occur in the rat pneumonia model after challenge with *Acinetobacter*. This supports our hypothesis that the immunocompetent rat pneumonia model is clinically relevant for assessing *A. baumannii* infection.

The rat soft-tissue infection model is clinically relevant for assessing *Acinetobacter* infection. Surgical sites, ulcers, and patients who have sustained traumatic (e.g., battlefield) in-
juries have been at risk for soft-tissue infection due to *Acinetobacter* (30, 48). Therefore, we tested our hypothesis that the immunocompetent rat soft-tissue infection model is clinically relevant for assessing *A. baumannii* infection. In brief, a subcutaneous fluid-filled space is created that can be inoculated with the bacterial strain being assessed, samples can be withdrawn, and bacterial titers can be measured over time (for at least 7 days). The growth of 307-0294 was assessed over 48 h (Fig. 7). Clearance was observed over the first 6 h, followed by growth and achievement of plateau density by 24 h. The ability of 307-0294 to survive the host’s defenses and proliferate within this soft-tissue environment is consistent with its ability to cause soft-tissue infection in humans. These data support our hypothesis that this model is clinically relevant and can be used to study *Acinetobacter* in this setting.

The rat soft-tissue infection model can be used to assess the relative virulence of various *A. baumannii* clinical isolates. Next we tested the hypothesis that the soft-tissue infection model could be used to discriminate between the inherent differences in virulence of various *A. baumannii* clinical isolates. The growth of 853 (OIFC031) (blood isolate, ST11, clonal group II), 855 (axillary isolate, ST14, clonal group III), 900 (perineal isolate, ST19, clonal group undetermined), and 979 (OIFC327) (environmental isolate, ST24, clonal group undetermined) was compared to that of 307-0294 in this model. Three patterns were observed: growth (979), clearance (853), or a variable degree of clearance over 3 to 6 h followed by different rates of growth (855/307-0294/900) (Fig. 7). There was a significant decrease or trend toward a significant decrease in survival of 853 and 900 at various times compared to 307-0294, 855, and 979. This model was quite sensitive in differentiating the abilities of different *A. baumannii* strains to survive in vivo. Interestingly, although the number of strains assessed was small, one might predict that survival of the blood isolates 307-0294 and 853 would be the greatest, but this was not the case. These data support our hypothesis that this model can be used to discriminate between the inherent differences in virulence of various *A. baumannii* clinical isolates.

Serum sensitivity of *Acinetobacter* isolates in vitro correlates with their growth in the soft-tissue infection model. Complement and neutrophils are innate host defense factors known to be active in the soft-tissue infection model (7, 8). Since various strains of *Acinetobacter* were variably cleared in this model, we hypothesized that complement is an important host factor in protecting against *A. baumannii* infection in vivo. Therefore, the serum sensitivity of *A. baumannii*...
strains 307-0294, 853, 855, 900, and 979 was assessed over 3 h in vitro (Fig. 8). All strains grew similarly in 90% serum that was heated at 56°C for 30 min to inactivate complement-mediated killing and LB medium (data not shown). When these strains were exposed to 90% active serum, the growth of 307-0294, 855, and 900 was similar. In contrast, 853 underwent an approximate 2-log killing and 900 underwent an approximate 0.5-log killing followed by recovery to the starting titer at 3 h; these differences were significant compared to 307-0294, 855, and 979. These data roughly correlate with growth/clearance in the soft-tissue infection model (Fig. 7). However, the soft-tissue infection model was more discriminatory, with 307-0294, 855, and 979 demonstrating differing growth/clearance capabilities, whereas in the serum sensitivity assay, the survival capabilities of 307-0294, 855, and 979 were similar. This is not surprising since multiple host defense factors (e.g., professional phagocytes and antimicrobial peptides) in addition to complement are present in the soft-tissue infection model. Nonetheless, these data support our hypothesis that complement is one host defense factor that contributes to the clearance of *A. baumannii* in vivo.

**FIG. 7.** Growth/clearance of *A. baumannii* strains 307-0294, 853, 855, 900, and 979 in the rat soft-tissue infection model. Rats were prepared and challenged with the bacterial strains being assessed as described in Materials and Methods. Bacterial titers were determined at 0, 3, 6, 24, and 48 h. There was a significant decrease or trend toward a significant decrease in survival of 853 and 900 at various times compared to 307-0294, 855, and 979. Data are means ± standard errors of the means for 4 to 6. *, 853 compared to 307-0294, *P* < 0.001 and 0.0005 at 3 and 6 h, respectively; #, 853 compared to 979, *P* = 0.0005 and 0.003 at 24 and 48 h, respectively. #, 853 compared to 307-0294, *P* = 0.045 at 24 h; #, 853 compared to 855, *P* = 0.03 at 24 h; #, 853 compared to 979, *P* = 0.02 and 0.03 at 3 and 6 h, respectively; *, 900 compared to 307-0294, *P* = 0.007 at 24 h; *, 900 compared to 855, *P* = 0.004 and <0.0001 at 24 and 48 h, respectively; *, 900 compared to 979, *P* = 0.002, 0.005, <0.0001, and <0.0001 at 3, 6, 24, and 48 h, respectively; #, 900 compared to 307-0294, *P* = 0.019 at 48 h. (Inset) Enlargement of data from 307-0294, 855, and 979 from 0 to 6 h. There was both a trend and a significant difference in growth of 307-0294 and 855 compared to 979. *, 855 compared to 979, *P* = 0.005; #, 307-0294 compared to 979, *P* = 0.02.

strains 307-0294, 853, 855, 900, and 979 was assessed over 3 h in vitro (Fig. 8). All strains grew similarly in 90% serum that was heated at 56°C for 30 min to inactivate complement-mediated killing and LB medium (data not shown). When these strains were exposed to 90% active serum, the growth of 307-0294, 855, and 900 was similar. In contrast, 853 underwent an approximate 2-log killing and 900 underwent an approximate 0.5-log killing followed by recovery to the starting titer at 3 h; these differences were significant compared to 307-0294, 855, and 979. These data roughly correlate with growth/clearance in the soft-tissue infection model (Fig. 7). However, the soft-tissue infection model was more discriminatory, with 307-0294, 855, and 979 demonstrating differing growth/clearance capabilities, whereas in the serum sensitivity assay, the survival capabilities of 307-0294, 855, and 979 were similar. This is not surprising since multiple host defense factors (e.g., professional phagocytes and antimicrobial peptides) in addition to complement are present in the soft-tissue infection model. Nonetheless, these data support our hypothesis that complement is one host defense factor that contributes to the clearance of *A. baumannii* in vivo.

**FIG. 8.** Effect of 90% normal human serum on the viability of the *A. baumannii* strains 307-0294, 853, 855, 900, and 979 in vitro. Assays were performed as described in Materials and Methods. All strains were also assessed in the presence of 90% heat-inactivated (56°C for 30 min) normal human serum, and their growth rates were similar; therefore, these data are not shown. The survival of 853 and 900 was significantly decreased compared to that of 307-0294, 855, and 979. Data are means ± standard errors of the means for 4 to 6. *, 853 compared to 307-0294, *P* < 0.0001 for all comparisons between 853 and 307-0294 and 979, *P* < 0.0001, 0.0006, and 0.002 for 853 compared to 855 for 1, 2, and 3 h, respectively; #, 900 compared to 307-0294, 855, and 979, *P* = <0.0001, 0.0006, and <0.0001 for 900 compared to 307-0294; *P* = 0.002, 0.008, and 0.009 for 900 compared to 855; *P* = 0.0004, <0.0001, and <0.0001 for 900 compared to 979 for 1, 2, and 3 h, respectively.
The rat soft-tissue infection model can be used to efficiently assess gene essentiality in vivo. Because safe reliable agents with predictable activity against *A. baumannii* are presently nonexistent, there is a need to identify new antimicrobial targets in *Acinetobacter*. Although multiple approaches to accomplish this goal exist, a starting point for one strategy is to identify *Acinetobacter* genes essential for growth. The rat soft-tissue infection model is an efficient model for assessing in vivo growth/survival because multiple samples can be obtained from a single animal over time. Therefore, we hypothesized that the soft-tissue infection model would serve as an effective screening tool for establishing gene essentiality for drug discovery. We randomly mutagenized 307-0294 using the transposon EZ-Tn5<kan-2>. Mutants isolated on MH plates containing kanamycin were subsequently gridded onto ascites plates supplemented with kanamycin. Chromosomal sequencing (using primers from the ends of EZ-Tn5<kan-2>) was performed on mutants that displayed no or minimal growth on ascites plates, enabling the localization of the transposon insertion. One of these mutants (307.5) contains a transposon insertion in the gene that codes for phosphoribosylaminomimidazole-succinocarboxamide synthase. Quantitative growth curves performed in LB medium demonstrated that there was no difference in growth between 307-0294 and 307.5 (data not shown). To test our hypothesis that the soft-tissue infection model could be used to establish gene essentiality in vivo, we assessed the growth of AB307.5 in this model (Fig. 9). 307.5, a mutant derivative of 307-0294, was cleared, thereby supporting our hypothesis.

**DISCUSSION**

*Acinetobacter* is a pathogen of increasing medical importance (13, 14, 19, 33). Little is known about its mechanisms of pathogenesis, vaccine candidates have not been identified, and an increasing proportion of strains are highly resistant to antimicrobials (29, 32). The availability of clinically relevant animal infection models will facilitate studies on the innate virulence of various *Acinetobacter* clinical isolates, potential virulence factors, vaccine candidates, and drug targets in vivo and can be used for pharmacokinetic and chemotherapeutic investigations. In this report we tested the hypotheses that the rat pneumonia and soft-tissue infection models that our laboratory had previously used for studies of extraintestinal pathogenic *E. coli* were clinically relevant for assessing *A. baumannii* (37, 41, 42). The lung is an important site of *Acinetobacter* infection in humans, and after challenge with *A. baumannii*, the pneumonia model demonstrated all of the features of infection that are critical for a clinically relevant model: namely, bacterial growth/clearance, an ensuing host inflammatory response, acute lung injury, and death due to respiratory failure following progressive bacterial proliferation (Fig. 1 to 6). Soft tissue has been increasingly recognized as an important site of *Acinetobacter* infection in battlefield injuries, surgical sites, and ulcers (5, 11, 18). We were also able to demonstrate growth of 307-0294 in the soft-tissue infection model, as occurs in soft-tissue infection, thereby supporting our hypothesis. We also hypothesized that the soft-tissue infection model could be used to discriminate between the inherent levels of virulence possessed by various *Acinetobacter* strains. In support of this, various patterns of growth were observed for the *Acinetobacter* strains tested (Fig. 7). Although it is beyond the scope of this report, these biologic data could be used in conjunction with molecular epidemiologic data as a means of predicting the virulence of *Acinetobacter* isolates. Given the variable growth of *Acinetobacter* strains in the soft-tissue infection model and the fact that complement is an active host defense factor in this site, we hypothesized that complement is an important host factor in protecting against *A. baumannii* infection in vivo. Growth/clearance of the *A. baumannii* strains in the soft-tissue infection model roughly correlated with growth/clearance in in vitro serum sensitivity studies (Fig. 8), thereby supporting this hypothesis. Lastly, we supported our hypothesis that the soft-tissue infection model could be used to establish the essentiality of *Acinetobacter* genes in vivo, an important characteristic for potential drug targets (Fig. 9). Although we did not utilize these models to assess vaccine candidates or virulence factors, it is self-evident that they can be used for this purpose as well.

The models described in this report have certain advantages over the previously described *Acinetobacter* animal infection models (4, 21, 22, 25–27, 31, 36). First, it is critical to be able to have bacterial growth over a significant period of time in a pneumonia model. In our rat model, with the highest challenge inocula we were able to demonstrate growth for 24 to 48 h post-bacterial challenge (Fig. 1). Further, at the highest challenge inocula some rats succumbed to infection (Fig. 2). Given that at these challenge inocula significant acute lung injury also occurred (Fig. 3 to 4), it is reasonable to infer that these animals died from respiratory insufficiency (as opposed to “cytokine storm”). Since we did not perform blood cultures in these animals, we cannot exclude the possibility of concomitant bacteremia, which could also contribute to mortality in this setting. However, even if bacteremia did occur in these animals, bacteremia also occurs in severe pneumonia in humans and as a result does not make this model less relevant. Taken together, these data support this model as being particularly relevant for studying all aspects of *Acinetobacter* pneumonia: namely, bacterial growth/clearance, acute lung injury, and the host response. In contrast, bacteria are often cleared in murine pneumonia models. Therefore, in the majority of *Acinetobacter* murine pneumonia models reported on to date, the animals received porcine mucin with the bacterial challenge (4, 25, 26, 34, 36) or were rendered neutropenic (20, 21), permutations
that are not present in most patients who develop *Acinetobacter* pneumonia. In one report that used a murine model, *Acinetobacter* grew over the first 4 h but underwent significant clearance by 24 h (22). A major advantage of the soft-tissue infection model is that multiple sampling can be performed over time in each animal, making it time and cost efficient for initial assessment of strains in vivo. In contrast, in the pneumonia models and thigh infection model (27) animals need to be euthanized for measurement of bacterial growth/clearance, injury, and the host response. Further, in the thigh infection model animals were rendered neutropenic (27). Although the lungs and soft tissue are clearly different host environments that contain different growth and host defense factors, clinical isolates and mutant derivatives of 307-0294 that were cleared in the soft-tissue infection model were also cleared when assessed in the pneumonia model (data not shown). Although we did not measure the host response in our *A. baumannii* studies, this can be done in the soft-tissue infection model as previously reported (7, 8). Therefore, the soft-tissue infection model is more cost-effective and high throughput for answering certain biologic questions. It would appear that this model could be used for an initial, efficient means to assess the growth/clearance of *Acinetobacter* in vivo.

Although it was not the main goal of this report, interesting aspects of *A. baumannii* biology were illuminated during this study. The soft-tissue infection model was more discriminating for growth differences between strains than for in vitro serum sensitivity testing (Fig. 7 and 8). This is not surprising since in the soft-tissue infection model host factors critical in protecting against extracellular bacterial pathogens like *Acinetobacter* are present including complement, antimicrobial peptides, and professional phagocytes. Second, *A. baumannii* strains 307-0294 and 853 were both blood isolates but displayed diametrically opposed growth/clearance patterns in vivo. These data highlight the fact that the innate virulence of clinical isolates may not necessarily be predicted by site of isolation.

In summary, we have supported our hypotheses on the utility of rat pneumonia and soft-tissue infection models for studying *Acinetobacter* biology. Both of the models described in this report are clinically relevant and possess certain advantages over previously described models. These models can be used to study the innate virulence of various *Acinetobacter* clinical isolates and to assess potential virulence factors, vaccine candidates, and drug targets in vivo and can be used for pharmacokinetic and chemotherapeutic investigations.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the financial support of a VA Merit Review from the Department of Veterans Affairs (T.A.R.) and a US Army Medical Research Acquisition Activity under contract W81XWH-05-1-0627 (T.A.R. and A.C.).

**REFERENCES**


Editor: V. J. DiRita